Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlowand FLT3-TKDand Role of Transplant in Patients over 60 Years of Age

MLA

Winer, Eric S., et al. “Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlowand FLT3-TKDand Role of Transplant in Patients over 60 Years of Age.” Blood, vol. 140, no. 1, Number 1 Supplement 1, Nov. 2022, pp. 6285–87. EBSCOhost, https://doi.org/10.1182/blood-2022-170587.

APA

Winer, E. S., Flamand, Y., Shallis, R. M., Stempel, J. M., Goldberg, A. D., Stahl, M. F., Patel, A. A., Duvall, A. S., Abaza, Y., Seijung Oh, T., Ma, K., Badar, T., Litzow, M. R., Kota, V., Bradshaw, D., Raman, H. S., Luskin, M. R., Stone, R. M., & DeAngelo, D. J. (2022). Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlowand FLT3-TKDand Role of Transplant in Patients over 60 Years of Age. Blood, 140(1, Number 1 Supplement 1), 6285–6287. https://doi.org/10.1182/blood-2022-170587

Chicago

Winer, Eric S., Yael Flamand, Rory Michael Shallis, Jessica M. Stempel, Aaron D Goldberg, Maximilian F. Stahl, Anand Ashwin Patel, et al. 2022. “Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlowand FLT3-TKDand Role of Transplant in Patients over 60 Years of Age.” Blood 140 (1, Number 1 Supplement 1): 6285–87. doi:10.1182/blood-2022-170587.